MedPath

Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma; a Pilot Study

Completed
Conditions
Surgery
Melanoma
Interventions
Procedure: Blood samples
Registration Number
NCT05817149
Lead Sponsor
Aalborg University Hospital
Brief Summary

We want to test if an association between sentinel lymph node biopsy (SLBN) and a systemic inflammatory response can be made.

Detailed Description

Sentinel lymph node biopsy (SLBN) is essential in staging melanoma and properly selecting patients for adjuvant immunotherapy. However, surgically induced inflammation can potentially aid in progression of remaining malignant cells and affect prognosis. The inflammatory marker neutrophil-to-lymphocyte ratio (NLR) is also a negative prognostic and predictive marker in serval malignancies, among melanoma. However, it is not yet established if SLNB induces a systemic inflammatory response.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Adult (>18 years of age)
  • Diagnosed with invasive cutaneous melanoma
  • Eligible for SLNB (Melanoma stage ≥ T1b)
  • Obtained signed informed consent
Exclusion Criteria
  • Pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with melanomaBlood samplesPatients with melanoma undergoing sentinel lymph node biopsy with perioperative blood samples.
Primary Outcome Measures
NameTimeMethod
Neutrophil-to-lymphocyte ratio1 Day

Ratio between neutrophil granulocytes and lymphocytes

Secondary Outcome Measures
NameTimeMethod
Pro-inflammatory cytokines1 Day

IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-α, and IFN-γ

Acute phase reactants1 Day

CRP, LDH

Trial Locations

Locations (1)

Aalborg University Hospital

🇩🇰

Aalborg, The North Denmark Region, Denmark

© Copyright 2025. All Rights Reserved by MedPath